News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,344 Results
Type
Article (8052)
Company Profile (140)
Press Release (476247)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166769)
Career Advice (305)
Deals (25742)
Drug Delivery (7)
Drug Development (52905)
Employer Resources (14)
FDA (9761)
Job Trends (8580)
News (238274)
Policy (17930)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33157)
ALS (104)
Alzheimer's disease (973)
Antibody-drug conjugate (ADC) (262)
Approvals (10367)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6962)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (506)
Cancer (3627)
Cardiovascular disease (217)
Career advice (245)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47855)
Collaboration (1236)
Commercialization (3)
Compensation (1445)
Complete response letters (34)
COVID-19 (766)
CRISPR (63)
C-suite (735)
Cystic fibrosis (85)
Data (5608)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4175)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73591)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87578)
Executive appointments (697)
FDA (12362)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (908)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (290)
Government (946)
Grass and pollen (2)
Guidances (281)
Healthcare (9312)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (954)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1969)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (505)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (527)
Marketing (8)
MASH (118)
Medical device (8651)
Medtech (8791)
Mergers & acquisitions (14377)
Metabolic disorders (703)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1816)
NextGen: Class of 2026 (3151)
Non-profit (841)
Obesity (222)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (501)
Peanut (31)
People (41207)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15466)
Phase 2 (21376)
Phase 3 (14399)
Pipeline (7160)
Policy (18)
Postmarket research (1570)
Preclinical (6537)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3019)
Recruiting (6)
Regulatory (14785)
Reports (19)
Research institute (581)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (320)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (93)
Last 7 days (497)
Last 30 days (1643)
Last 365 days (19131)
2026 (11939)
2025 (19251)
2024 (22988)
2023 (26542)
2022 (34592)
2021 (37179)
2020 (33497)
2019 (23259)
2018 (17494)
2017 (18766)
2016 (17920)
2015 (24264)
2014 (21679)
2013 (18135)
2012 (20222)
2011 (20442)
2010 (20333)
Location
Africa (229)
Alabama (72)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17882)
Australia (2097)
California (11864)
Canada (3116)
China (515)
Colorado (479)
Connecticut (405)
Delaware (207)
Europe (24630)
Florida (1773)
Georgia (372)
Hawaii (3)
Idaho (46)
Illinois (695)
India (48)
Indiana (314)
Iowa (14)
Japan (397)
Kansas (100)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1188)
Massachusetts (7806)
Michigan (306)
Minnesota (558)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2602)
New Mexico (12)
New York (2799)
North Carolina (1263)
North Dakota (4)
Northern California (5938)
Ohio (275)
Oklahoma (14)
Oregon (18)
Pennsylvania (2241)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4923)
Tennessee (119)
Texas (1915)
United States (38555)
Utah (357)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (919)
West Virginia (1)
Wisconsin (73)
484,344 Results for "medicago inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Medicago submits Phase 3 data to Health Canada for its plant-based COVID-19 vaccine candidate
Medicago, a biopharmaceutical company headquartered in Quebec City, is pleased to announce submission of the positive Phase 3 data for regulatory review by Health Canada as part of the New Drug Submission for COVID (NDS-CV) rolling review for Medicago’s COVID-19 vaccine candidate combined with GSK’s pandemic adjuvant.
December 16, 2021
·
3 min read
Business
Medicago announces the appointment of Toshifumi Tada as President and CEO
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, announced the appointment of Toshifumi Tada as President and chief executive officer, effective on May 1, 2022.
April 28, 2022
·
2 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Policy
Health Canada authorizes Medicago COVID-19 vaccine for adults 18 to 64 years of age
Health Canada authorized Medicago’s Covifenz COVID-19 vaccine for the prevention of COVID-19 in adults 18 to 64 years of age.
February 24, 2022
·
2 min read
Drug Development
Clinical Catch-Up: Pfizer’s Paxlovid Gaff, a Win for Medicago-GSK’s Vaccine
Pfizer’s Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
May 6, 2022
·
9 min read
·
Mark Terry
Drug Development
Medicago announces publication of Phase 3 COVID-19 vaccine study results in New England Journal of Medicine
Medicago today announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine (plant-based virus-like particles [VLP], recombinant, adjuvanted), in the New England Journal of Medicine (NEJM).
May 5, 2022
·
2 min read
Job Trends
Medicago and GSK Announce the Approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
February 24, 2022
·
5 min read
Drug Development
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
Medicago, today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.
December 7, 2021
·
7 min read
Job Trends
Medicago and GSK announce the approval by Health Canada of COVIFENZ, an Adjuvanted Plant-Based COVID-19 Vaccine
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
February 24, 2022
·
4 min read
Takashi Nagao appointed President and Chief Executive Officer of Medicago
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today.
December 4, 2020
·
3 min read
1 of 48,435
Next
